ADMA BiologicsADMA +2.35%64 Receivables Turnover is 0.78 as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.02 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 839 Biotechnology companies, ADMA Biologics ranks worse than 64.36% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ADMA Biologics's Revenue for the
three
months ended in Mar. 2026 was $114.5 Mil. ADMA Biologics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $147.1 Mil.
Hence, ADMA Biologics's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.78.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ADMA Biologics Receivables Turnover Related Terms
ADMA Biologics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Receivables Turnover Comparison
For the Biotechnology subindustry, ADMA Biologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Receivables Turnover of 0.78 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #540 out of 839 companies in the Biotechnology industry, placing it in the top 64.4%.
Is ADMA Biologics' Receivables Turnover too high?
ADMA Biologics' current Receivables Turnover is 0.78. The Biotechnology industry median Receivables Turnover is 5.27. ADMA Biologics' value of 0.78 is 85.2% below this industry median. Based on the distribution chart, ADMA Biologics ranks #540 out of 839 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Receivables Turnover compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #540 out of 839 companies for Receivables Turnover. This places ADMA Biologics in the lower half of its industry. The industry median Receivables Turnover is 5.27. ADMA Biologics' value of 0.78 is 85.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Receivables Turnover of 0.78 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Receivables Turnover is 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.02, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current Receivables Turnover is 0.78 and 85.2% below the Biotechnology industry median of 5.27. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Receivables Turnover is 0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.02.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Receivables Turnover: 0.78
GF Value™: $18.02 vs. price of $9.16 (49.2% below fair value)
Industry Position: 85.2% below the Biotechnology median (#540 of 839)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
